Apart from calvarial infiltration, intracranial involvement in multiple myeloma is uncommon. Diffuse leptomeningeal invasion with or without parenchymal involvement is most common. Dural infiltration without involvement of the parenchyma, leptomeninges or skull is rare. The differential diagnosis of a dural plasmacytoma includes meningioma, which has a similar MRI appearance, metastasis, lympho...

The author studied 133, 856 admissions over a ten-year period and found 138 cases of primary tumors of bone. Of these only 33 were multiple myeloma. Incidence, clinical manifestation, age, sex and etiology are reported, and the effect of four different chemotherapy regimens are evaluated.

Because multiple myeloma remains associated with a poor prognosis, novel drugs targeting specific signaling pathways are needed. The efficacy of selective estrogen receptor modulators for the treatment of multiple myeloma is not well documented. In the present report, we studied the antitumor activity of raloxifene, a selective estrogen receptor modulator, on multiple myeloma cell lines. Raloxi...

Because multiple myeloma remains associated with a poor prognosis, novel drugs targeting specific signaling pathways are needed. The efficacy of selective estrogen receptor modulators for the treatment of multiple myeloma is not well documented. In the present report, we studied the antitumor activity of raloxifene, a selective estrogen receptor modulator, on multiple myeloma cell lines. Raloxi...

Address for correspondence Dr.Arathi.N, 173, 12-B Main, 6th Block, Rajajinagar,Bangalore-560010,India. E Mail:[email protected] Mob: +91 9568184651 Asian Journal of Medical and Clinical Sciences Original Article

n/a.

Treatment regimens for multiple myeloma are evolving because of new advances in both pharmacotherapy and transplantation strategies. The Multiple Myeloma Research Foundation (MMRF) has gathered the top thought leaders in myeloma research to prepare an engaging, interactive series of case studies in multiple myeloma, which are available online at www.multiplemyeloma.org and are published on a re...

Multiple myeloma is a plasma cell malignancy that homes aberrantly to bone causing extensive skeletal destruction. Despite the development of novel therapeutic agents that have significantly improved overall survival, multiple myeloma remains an incurable disease. Matrix metalloproteinase-2 (MMP-2) is associated with cancer and is significantly overexpressed in the bone marrow of myeloma patien...

Multiple myeloma is still an incurable hematological malignancy despite the development of high-dose chemotherapy with stem cell transplantation. However, the therapeutic approach for multiple myeloma has progressed significantly in the last decade. Novel agents such as bortezomib, thalidomide and lenalidomide have been introduced in clinics as expanded treatment options and have improved the o...